Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
Asahi Kasei Pharma is confident that it can achieve the group’s goal of lifting global pharmaceutical sales to at least 300 billion yen in FY2030, President Yoshikazu Aoki told Jiho, calling the target “well within reach” and adding that it…
To read the full story
Related Article
- Asahi Kasei Sees Tarpeyo Uptake Outpacing Forecast, Peak Sales Can Be Higher
January 9, 2026
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- Asahi Kasei on Hunt for M&A and Licensing Deals to Bolster Pharma Biz
April 15, 2025
- Asahi Kasei to Divest Diagnostics Biz to Nagase in July 2025
September 27, 2024
- Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
- Asahi Kasei to Divest Medical Devices Unit to Integral, but Retains Bioprocess Biz
September 19, 2024
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- Asahi Kasai to Integrate Japan and US Pharma Biz by March 2026
May 21, 2024
BUSINESS
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- Kyowa Kirin Targets 20-Plus New Pipeline Assets by Early 2030s
February 10, 2026
- Kyowa Kirin’s FY2025 Core Operating Profit Hits Record High as Costs Fall
February 10, 2026
- Eisai CFO Casts Oncology Pipeline Expansion as Urgent Task
February 10, 2026
- Pharma Fears Off-Year Price Reform Loses Traction after LDP Sweep
February 10, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…